Sign up to save your podcasts
Or
Share The Future of Cell and Gene Therapies, with E&Y’s Adlai Goldberg
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
The Future of Cell and Gene Therapies, with E&Y’s Adlai Goldberg
The cell and gene therapy sector is on the cusp of flourishing in the vast pharma landscape. Money is flowing in, manufacturing challenges are being overcome, people are actually being treated and cured. Even COVID-19 may be seen as a driving force for the burgeoning sector. But what does the future hold? Ernst & Young’s Adlai Goldberg describes the steps industry must take to advance the advanced therapy space and how it must move to balance the individualized autologous approach with more sustainable allogeneic products.
Keep up with BioProcess Insider on our website.
Follow us on LinkedIn and Twitter:
- @BioProInsider
View all episodes
By Dan Stanton
5
22 ratings
The cell and gene therapy sector is on the cusp of flourishing in the vast pharma landscape. Money is flowing in, manufacturing challenges are being overcome, people are actually being treated and cured. Even COVID-19 may be seen as a driving force for the burgeoning sector. But what does the future hold? Ernst & Young’s Adlai Goldberg describes the steps industry must take to advance the advanced therapy space and how it must move to balance the individualized autologous approach with more sustainable allogeneic products.
Keep up with BioProcess Insider on our website.
Follow us on LinkedIn and Twitter:
- @BioProInsider